Related Experiment Videos
Treatment of central serous chorioretinopathy with beta-blocker metipranolol
Oldrich Chrapek1, Barbora Jirkova, Vit Kandrnal
1Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Aim:
The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC).
Methods:
A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium.
Results:
There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341).
Conclusions:
In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Angle Closure Glaucoma: Treatment
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers